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ABSTRACT: 
Influenza A is a rapid evolving virus, successful in provoking periodic epidemics and 
occasional pandemics in humans. Viral assembly is complex as the virus incorporates an eight-
partite segmented genome of RNA (in the form of viral ribonucleoproteins, vRNPs). Genome 
assembly, with implications to public health, is not completely understood. It was reported that 
vRNPs are transported to the cell surface on Rab11 vesicles using microtubules, but no 
molecular motor has been assigned to the process. Here, we have identified KIF13A, a member 
of the kinesin-3 family, as the first molecular motor efficiently transporting vRNP-Rab11 vesicles 
during IAV infection. Depletion of KIF13A resulted in reduced viral titres and less accumulation 
of vRNPs at the cell surface, without interfering with the levels of other viral proteins at sites of 
viral assembly. In addition, in overexpression conditions and using two artificial methods able to 
displace vRNP-Rab11 vesicles, KIF13A augmented vRNP levels at the plasma membrane. 
Together our results show that KIF13A is an important host factor promoting influenza A vRNP 
transport, which is a crucial step for viral assembly. 
 
SUMMARY STATEMENT: 
Progeny RNA from influenza A virus is transported to the cell surface on vesicles of the 
recycling endosome to be packaged into assembling virions. Here, we have identified the first 
molecular motor, KIF13A, able to carry these vesicles and positively influence the localization of 
vRNPs at the cell surface and viral assembly.    
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INTRODUCTION: 
Influenza A virus (IAV) genome is single-stranded of negative-sense RNA and 
segmented, divided into eight independent replication units. Each unit is composed of identical 
RNA termini, and the 3’ and 5’ are partially complementary and form a dsRNA region that 
accommodates the viral heterotrimeric RNA dependent RNA polymerase (RdRp) (Pflug et al., 
2014). The remainder RNA contains distinct coding regions, of variable sizes coated by 
nucleoprotein (NP) molecules which are placed every 24 nucleotides on average (Arranz et al., 
2012). In the virion, the eight distinct viral ribonucleoproteins (vRNPs) occupy the inner core and 
are spatially distributed with seven segments surrounding a central one in a “7+1” arrangement 
(Noda and Kawaoka, 2010). Of the up to 18 identified proteins encoded by the virus (Yamayoshi 
et al., 2015), only 5 additional viral factors to those forming vRNPs are essential structural 
components of the virion. The viral nuclear export protein (NEP) is found attached to vRNPs in 
modest amounts. Surrounding the genomic core is a layer of the matrix protein 1 (M1), that is 
coated by a host derived membrane containing 3 antigenic viral transmembrane proteins: 
hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2) (Hutchinson et al., 2014, 
Shaw et al., 2008).  
The mechanisms underlying virion formation inside the host cell are not fully understood. 
Viral assembly comprises the formation of the supra-molecular complex described above at the 
cell surface, and propels viral budding and release. Viral genome complex formation has been 
reported to be fully dependent on the establishment of RNA-RNA interactions between the 
different vRNPs (as reviewed in (Gerber et al., 2014, Giese et al., 2016, Hutchinson et al., 
2010)). However, IAV assembly is heavily dependent on host processes, namely for transporting 
components to the budzone. The transport of the viral transmembrane proteins, HA, NA and M2 
to the plasma membrane occurs via the secretory pathway (Doms et al., 1993) and involves the 
coat protein I (Sun et al., 2013). M1 might be transported along with vRNPs (Noton et al., 2007), 
M2 (Chen et al., 2008) and/or lipids to the surface, but a detailed analysis of the transport of the 
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M1 pool included in virions is still missing. In the case of vRNPs, the eight-distinct segments are 
synthesized in the host cell nucleus as independent entities, exported to the cytoplasm (Elton et 
al., 2001, Ma et al., 2001) and transported to the surface. The endocytic recycling compartment 
(ERC) was shown to be required for this transport, with vRNPs binding to the major coordinator 
of ERC trafficking, the GTPase Rab11 (Amorim et al., 2011, Avilov et al., 2012, Eisfeld et al., 
2011, Momose et al., 2011). In the healthy cell, Rab11 is switched off or on by binding to GDP 
or GTP, respectively (Xiong et al., 2012). Activated Rab11 acquires sequential affinity for a 
series of molecular motors, membrane tethers and v-SNARES, responsible for vesicular 
movement along cytoskeletal tracks, attachment to and fusion with membranes, respectively 
(Welz et al., 2014). In relation to molecular motors, Rab11 vesicles were reported to associate 
with: myosin Vb, dynein light chain 1 and 2, KIF5a and KIF3 of the kinesin-1 and -2 families, 
respectively ((Fan et al., 2004, Lapierre et al., 2001, Provance et al., 2008, Roland et al., 2011, 
Schonteich et al., 2008, Perez Bay et al., 2013) and reviewed in (Vale-Costa and Amorim, 
2016b)). Interestingly, these motors require adaptors for Rab11 binding, and these adaptors 
belong to a vast family collectively called Rab11-interacting-proteins (FIPs) (Horgan and 
McCaffrey, 2009). Recently, Rab11 vesicles were shown to associate with an additional motor, 
KIF13A, from the kinesin-3 family, without recurring to FIPs for binding (Delevoye et al., 2014). 
In infection, IAV modulates Rab11 trafficking and, as a consequence, this dynamic chain of 
events is altered. Known effectors of Rab11 are prevented from binding to Rab11 (Vale-Costa et 
al., 2016), transferrin recycling is reduced (Kawaguchi et al., 2015, Vale-Costa et al., 2016), and 
FIPs that are essential components of the pathway were found to be dispensable for IAV 
infection (Bruce et al., 2010, Momose et al., 2011). Mechanistically, vRNPs were found to out-
compete FIPs for Rab11 binding (Vale-Costa et al., 2016). Therefore, although several papers 
have confirmed the importance of Rab11 for vRNP delivery to the surface (Amorim et al., 2011, 
Avilov et al., 2012, Eisfeld et al., 2011, Momose et al., 2011) and viral assembly (Chou et al., 
2013, Lakdawala et al., 2014), it is unclear which host factors are involved in transporting 
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vRNPs to sites of viral assembly. In particular, no molecular motor was identified as being able 
to transport vRNP-Rab11 vesicles, and it is unknown if vesicular movement on microtubules is 
modified by the virus. On the one hand, vRNPs were shown to transit with directed and 
intermittent movements, with speeds compatible with using microtubule and actin (Amorim et al., 
2011, Avilov et al., 2012). Consistent with the usage of the cytoskeleton, NP was shown to co-
localise with actin (Avalos et al., 1997, Digard et al., 1999, Roberts and Compans, 1998, 
Simpson-Holley et al., 2002), and pharmacological destabilization of the microtubule network 
disrupted shuttling of vRNPs to the plasma membrane (Amorim et al., 2011). On the other hand, 
drugs acting on actin or microtubule integrity have mild effects in viral production (Amorim et al., 
2011, Momose et al., 2007, Simpson-Holley et al., 2002), despite impacting dramatically in virion 
morphology (Roberts and Compans, 1998, Simpson-Holley et al., 2002). Furthermore, as vRNP 
binding to Rab11-GTP out-competed the binding of FIPs, it is possible that the vesicular flow is 
compromised upon infection (Momose et al., 2011, Vale-Costa et al., 2016). In agreement, it 
was shown that vRNPs associate with Rab11a at ∼300 nm from the nucleus but disassociate at 
∼500 nm from the cell surface (Nturibi et al., 2017), which indicates that Rab11 might not be the 
final factor delivering vRNPs to the plasma membrane (Eisfeld et al., 2015, Vale-Costa and 
Amorim, 2016a). 
Here, we report that KIF13A positively modulates IAV infection, affecting the trafficking 
and peripheral localization of vRNPs, but not of the viral transmembrane proteins HA and M2. 
Depletion of KIF13A did not disturb the initial steps of viral infection, including viral entry, 
replication and gene expression. Our results suggest a model in which vRNP transport is 
facilitated by KIF13A on Rab11 vesicles and not by molecular motors that require FIPs for 
association to Rab11. 
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 RESULTS: 
KIF13A depletion reduces viral production  
To answer whether KIF13A is necessary for IAV infection, we depleted cells of this 
molecular motor with specific siRNAs (Fig 1A-B, S1), infected or mock-infected cells with 
influenza A/Puerto Rico/8/34 (PR8) and quantified viral production. KIF13A-depleted cells 
resulted in over 10 and 5-fold reduction in viral titers relative to cells treated with non-targeting 
siRNAs (siNT) at 6 and 10h p.i., respectively, showing that KIF13A is required for the virus life-
cycle (Fig 1A). When KIF13A mRNA levels were quantified, a consistent average depletion of 
80% in mock-infected cells was obtained. In infected cells, depletion was not as efficient 
averaging 70%, and 60% reduction at 6 and 10h p.i.. Interestingly, infection specifically targets 
KIF13A for depletion, especially late in infection, as cells treated with non-targeting siRNAs 
consistently exhibited a drop of roughly 60% at 10h p.i. (Fig 1B). The significance of this has not 
been explored further but suggests a viral induced restriction in KIF13A amounts. Endogenous 
levels of KIF13A protein were just above the detection limit and depletion was difficult to quantify 
(Fig S1A). Western blot analysis showed no detectable differences in viral gene expression (Fig 
1C,D) between the two siRNA treated samples in the times analysed.  Our results suggest that 
KIF13A does not affect the initial steps of viral infection, since viral protein expression is similar 
in cells with and without KIF13A. To evaluate knock-down levels of KIF13A protein, we 
transfected GFP or GFP-KIF13A-WT or a siRNA-resistant GFP-KIF13A form, treated cells with 
specific RNAs concomitantly, observing that KIF13A depletion at the protein level was very 
efficient (Fig S1B).  
Our results indicate that KIF13A is required for IAV lifecycle, at a step downstream of 
vRNP nuclear import and viral mRNA synthesis.  
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 KIF13A depletion influences vRNP transport but not that of HA and M2  
Given that KIF13A was shown to bind and transport Rab11 vesicles (Delevoye et al., 
2014), and vRNPs were shown to use Rab11 vesicles for reaching sites of assembly (Amorim 
et al., 2011, Avilov et al., 2012, Eisfeld et al., 2011, Momose et al., 2011), we sought to observe 
the effect of KIF13A-depletion in vRNP localization during the course of infection. It is well-
established that at early time points, vRNPs accumulate in the nucleus (where they are 
synthesized) and from 6h onwards localise mainly in the cytoplasm. Cytosolic vRNPs start by 
accumulating at the microtubule organizing center and then become disperse throughout the 
cytosol, co-localising with the host protein Rab11 in puncta that enlarge over time (Amorim et 
al., 2011). Enlarged puncta were shown to correspond to clustered vesicles that result from 
impaired vesicular flow (Vale-Costa et al., 2016, Vale-Costa and Amorim, 2016a). The 
nuclear/cytoplasmic time-dependent changes in vRNP localization as assessed by NP staining 
(Fig 2A,B) and Pearson correlation values (Fig 2C) between vRNPs and Rab11 were not 
statistically different in cells treated with KIF13A and non-targeting siRNAs. This indicates that 
in the absence of KIF13A, vRNPs still co-localise with Rab11, suggesting that the lack of this 
molecular motor does not interfere with loading of progeny RNA into recycling membranes. 
However, the accumulation of vRNPs at the periphery was significantly lower in KIF13A-
depleted cells (Fig 2E). Thus, we concluded that depletion of KIF13A is required for the 
peripheral positioning of vRNPs. Interestingly, the progressive enlargement in Rab11 and 
vRNPs cytoplasmic areas previously reported (Amorim et al., 2011, Chou et al., 2013, Eisfeld et 
al., 2011, Lakdawala et al., 2014, Vale-Costa et al., 2016) was reduced relative to the control 
(Fig 2D), suggesting either a decrease in vesicular biogenesis or movement (Delevoye et al., 
2014) in the absence of KIF13A.  
We also asked whether KIF13A interfered with the levels of the viral transmembrane 
proteins HA and M2 that are delivered to the surface by a membrane trafficking pathway 
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independent of Rab11 (Doms et al., 1993). Cells were treated with control and KIF13A specific 
siRNAs, and challenged with PR8. At 10h p.i. the surface levels of HA and M2 were measured 
by flow cytometry. KIF13A-depleted cells presented higher amounts (~150% and ~130%, 
respectively) of these two viral proteins at the surface when compared to control cells (Fig 2F). 
As previously proposed (Amorim et al., 2013), this result suggests that HA and M2 proteins are 
transported to the cell surface normally, but are not released because of reduced viral egress.  
Our data strongly indicate that KIF13A influences the low of vRNPs on Rab11 vesicles 
without interfering with the trafficking of other viral transmembrane proteins.  
 
KIF13A overexpression biases vRNP distribution to the periphery  
 Our data indicates that KIF13A impacts on vRNP cytoplasmic distribution. To 
strengthen this observation, cells were transfected with GFP as control, or with either a GFP 
tagged full-length KIF13A (GFP-KIF13A-WT, henceforward KIF13A-WT) or a truncated form 
able to attach vesicles but not microtubules (GFP-KIF13A-ST, henceforward KIF13A-ST) that 
was described in (Delevoye et al., 2014) and here in Fig 3D. Cells were subsequently infected or 
mock infected with PR8, and NP distribution assessed during infection. In mock infected cells, 
the three proteins distributed as described before (Delevoye et al., 2014). GFP dispersed 
throughout the cytosol (Figs 3A, S2A, S3). KIF13A-WT, was found in the cytosol (in tubules and 
puncta), accumulating in peripheral spots (Fig 3B, S2B, S3B), partially co-localising with Rab11 
(Fig 3B). KIF13A-ST localized to cytosolic puncta also occupied by Rab11 (Fig 3C, S2C, S3C). 
In infected cells transfected with GFP, NP displayed similar time-dependent changes in 
localization to those described above (Amorim et al., 2011, Amorim et al., 2013, Vale-Costa and 
Amorim, 2016a): early nuclear accumulation, followed by cytoplasmic display from 6h onwards. 
The cytoplasmic phase of vRNPs included the initial accumulation of vRNA in discrete puncta 
(and perinuclar accumulation) and at later time points, the discrete puncta were replaced by 
larger structures dispersed throughout the cytoplasm (Figs 3A, S2A, S4A). The overexpression 
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of KIF13A-WT resulted in extensive tubulation of the membrane associated with vRNPs, in close 
proximity to KIF13A tracks (Fig 3B). Further, it led to the accumulation of vRNPs at the periphery 
in areas containing Rab11 agglomerates and KIF13A (Figs 3B, S2B, S4B (untreated).To 
understand whether KIF13A-dependent vRNP peripheral localization required its motor activity, 
the distribution of NP was assessed in cells expressing KIF13A-ST. Strikingly, NP localization 
was similar to that observed in the GFP control, and at 8 and 10h p.i. KIF13A-ST was found 
juxtaposed (partially co-localising with) vRNP-Rab11 enlarged puncta (Fig 3C, S2C, S2D, S4C 
(untreated)). To measure the vRNP peripheral accumulation in the different conditions over the 
course of infection, we applied the same method as in Fig 2E. NP peripheral localization 
(relatively to the whole cell) in cells challenged with PR8 and transfected with either GFP or 
KIF13A-ST did not differ during the course of infection. However, NP peripheral localization in 
cells transfected with KIF13A-WT was significantly higher than the other conditions at the times 
tested. Our results, therefore, show that KIF13A can influence the distribution of vRNP-
containing-Rab11 vesicles using its motor activity. 
KIF13A was shown to interact with the three isoforms of Rab11 (Rab11a, Rab11b and 
Rab25) by yeast two hybrid systems and pull down assays (Nakagawa et al., 2000, Delevoye et 
al., 2009, Delevoye et al., 2014). Rab11a and Rab11b are highly homologous and are both 
implicated in IAV infection (Bruce et al., 2010). Attempts to observe a complex between vRNP-
Rab11-KIF13A at endogenous levels failed. In cells overexpressing GFP or KIF13A-WT or 
KIF13A-ST and cherry-Rab11a WT or cherry-Rab11b WT, Rab11a and Rab11b were selectively 
pulled down with both forms of KIF13A in mock and infected cells at very low, but similar levels 
(Fig 4). This result suggests that infection does not change this interaction, conversely to what 
was described for FIPs (Vale-Costa et al., 2016). However, the low levels of Rab11a/b 
selectively purified with KIF13A were insufficient to specifically pull down vRNPs (Fig 4), and 
whether vRNPs form a tripartite complex together with Rab11 and KIF13A remain to be 
explored.  
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vRNP agglomeration induced by the drug nucleozin is affected by KIF13A overexpression  
Given that we found no biochemical association between KIF13A-Rab11-vRNPs, we 
sought to confirm if KIF13A impacts the vRNP distribution in IAV infected cells using several 
additional complementary strategies. First, we used the drug nucleozin (Kao et al., 2010), 
previously demonstrated to permanently bind colliding vRNP-Rab11-vesicles when added at late 
time points (Amorim et al., 2013). Briefly, the drug was shown to have affinity for several 
domains on NP (the viral protein coating vRNPs) (Kao et al., 2010), and hence, when vesicles 
(carrying vRNPs on the outside) collide, they attach to each other. As time progresses, 
nucleozin induced vRNP-Rab11-vesicular agglomerates increase in size, producing dramatic 
structures that collapse near the microtubule organizing center (minus-end) (for detailed 
description on nucleozin readers are referred to (Kao et al., 2010, Amorim et al., 2013)). Of note, 
as nucleozin has affinity for NP and not Rab11, its action is specific to infected cells ((compare 
treated/untreated samples in Figs S3, S4) and (Amorim et al., 2013)). Conversely to the 
nucleozin induced movement of vRNPs to the perinuclear region, KIF13A transports Rab11 
vesicles towards the plus-end (or the cell surface) (Delevoye et al., 2014). Hence, we reasoned 
that KIF13A would counteract the action of nucleozin by applying a force in the opposite 
direction that would either alter a) the shape of agglomerated vesicles or b) the time 
agglomerates take to collapse at the perinuclear region (Fig 5C).  
Consistent with exerting opposing forces, nucleozin treated cells overexpressing KIF13A-
WT originated vRNP-agglomerates more distant from the nucleus than those observed in cells 
expressing GFP (as control) or KIF13A-ST (without motor capacity) (Fig 5A). For an unbiased 
and accurate quantification of nucleozin induced perinuclear accumulation of vRNPs/Rab11, we 
generated an automated tool to evaluate the amount of vRNPs/Rab11 within 2 μm from the 
nucleus (Fig 5B). Both NP and Rab11 staining were significantly less intense close to the 
nucleus in cells overexpressing KIF13A-WT treated with nucleozin when compared to those in 
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cells with GFP or KIF13A-ST, indicating that KIF13A operates as a force able to counteract 
nucleozin action (Fig 5B). 
Nucleozin induced vRNP-agglomerates were shown to include Rab11 ((Amorim et al., 
2013) and Fig 5D (right)) but exclude a series of organelle markers (Golgi, endoplasmic 
reticulum, lysosomes). We reasoned that given that the candidate proteins exhibit similar 
dynamics of colocalization with the vRNPs and are specifically trapped in nucleozin-induced 
vRNP aggregates, this strongly suggests that they form functional complexes with the vRNPs 
(Amorim et al., 2013). To understand if this was the case for KIF13A, we quantified Pearson 
correlation values of GFP, KIF13A-WT, KIF13A-ST with vRNPs and Rab11. GFP and KIF13A-
WT were found not to co-localise with vRNPs or Rab11 in infected cells, regardless of nucleozin. 
However, as just demonstrated, KIF13A-WT counteracts nucleozin induced aggregate formation 
by exerting a force in the opposite direction, and with GFP fused to the motor part, proximity 
between all components could be hard to evaluate in this system. Hence, we reasoned that 
KIF13A-ST would be a better choice for this measurement, as it is devoid of the pulling capacity. 
In agreement, in the presence of nucleozin, KIF13A-ST co-localised with both vRNPs and 
Rab11, consistent with being in close proximity (Fig 5D). Together, our results suggest that 
KIF13A not only influences the location of vRNPs and Rab11 in infected cells, but might also be 
part of a complex with these vesicles. 
 
KIF13A biases mitoRab11-vRNP distribution to the surface 
As a second additional strategy to understand if KIF13A transports vRNPs on Rab11 
vesicles and as a way to discriminate if it binds to either Rab11a and Rab11b, we used an 
artificial targeting system to anchor Rab11a and Rab11b to the mitochondria (by fusing 
Rab11a/b constitutively active (CA) with the mitochondrial targeting sequence (MTS) of Tom20 
(henceforward mitoRab11a/b)) and analyse relocation of individual effectors (Fig 6B). This 
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strategy has been successfully used by us to show that FIPs competed with vRNPs for Rab11a 
binding (Vale-Costa et al., 2016). MitoRab11aCA but not mitocherry control recruited FIPs to the 
mitochondria ((Vale-Costa et al., 2016) and Fig S5A). When vRNPs and FIPs were co-
expressed, a decrease in vRNP localization to the mitochondria was observed (Vale-Costa et 
al., 2016). We applied the same protocol here and transfected mitocherry or mitoRab11a/b and 
GFP or KIF13A-WT or KIF13A-ST to mock and infected cells. In mock or infected cells, GFP 
and KIF13A-WT did not relocalize to the mitochondria (Fig 6, S5B,C, S6). However, KIF13A-ST, 
in the presence of mitoRab11a, but not mitocherry, was found juxtaposed to this organelle (Fig6, 
S5B,C, S6), indicating that, if not part of the complex, this motor (when not exerting pulling 
forces) is found in close proximity to mitoRab11a. In infection, vRNPs redistributed to the 
mitochondria in an undifferentiated manner regardless of KIF13A (Fig S5 and 6A-C). 
Furthermore, overexpression of KIF13A-WT biased the distribution of mitoRab11a (Figs 6A,C, 
S5B,C middle panels, S6) and of vRNPs to places at the cell surface displaying KIF13A-WT 
(Figs 6, S5C). Similar observations were acquired for mitoRab11b. Quantification of peripheral 
localization of mitoRab11a or mitoRab11b, and of vRNPs was done by measuring the 
percentage of these components within 3μm of the plasma membrane relative to the whole cell 
(3μm were chosen given the large size of mitochondria). In the presence of KIF13A-WT, 
mitoRab11a/b and vRNPs were found significantly closer to the periphery than the control GFP, 
confirming the results obtained. In addition, this biased localization was, at least for mitoRab11b 
and vRNPs dependent of the motor activity of KIF13A, as the -ST form failed to do so with the 
same extent (Figs 6C,D, S5,6). 
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 DISCUSSION: 
It was shown that vRNPs are transported to the cell periphery using the recycling pathway 
(via Rab11) at speeds compatible with movement along microtubules (Amorim et al., 2011, 
Avilov et al., 2012, Eisfeld et al., 2011, Momose et al., 2011). In addition, it is well established 
that IAV not only uses the recycling pathway but alters it, as demonstrated by Rab11 
redistribution during infection, changing from distinct puncta to enlarged structures (Lakdawala 
et al., 2014, Chou et al., 2013, Amorim et al., 2011, Avilov et al., 2012, Eisfeld et al., 2011). 
Mechanistically, Rab11 alterations were reported to be, at least partially, a consequence of a 
viral-induced halt in recycling endosome functioning (Vale-Costa et al., 2016, Vale-Costa and 
Amorim, 2016a). Several lines of evidence support this hypothesis including reduction in 
transferrin recycling upon infection (Kawaguchi et al., 2015, Vale-Costa et al., 2016) and in 
recruitment of bona fide Rab11 effectors, as well as the demonstration that Rab11 enlarged 
puncta were composed of clustered vesicles (Vale-Costa et al., 2016, Vale-Costa and Amorim, 
2016a), containing the a pool of the eight vRNPs (Chou et al., 2013, Lakdawala et al., 2014). 
Whether vesicular clustering serves a function has not been determined. One appealing 
hypothesis is that these sites might serve to concentrate vRNPs and promote viral genome 
assembly. Such hypothesis contrasts other recently proposed models suggesting that genome 
assembly occurs gradually as ERC vesicles collide on route to the plasma membrane, with the 
sequential formation of vRNP sub-bundles (with less than eight vRNPs) as reviewed in 
(Lakdawala et al., 2016). The latter model is supported by an increase in co-localisation of the 
eight segments found in the Rab11 enlarged structures. Approaches able to resolve whether in 
clustered vesicles (or Rab11 enlarged structures), the eight segments are found in a complex 
are necessary to validate one of the models. 
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IAV modulation of the recycling pathway (Rab11 vesicles) and, in particular, competition 
between vRNPs and FIPs for Rab11 binding, raised the important question of which host 
factors, with special attention to molecular motors, were involved in carrying vRNP laden-Rab11 
vesicles to the cell periphery (Amorim et al., 2011, Eisfeld et al., 2011, Avilov et al., 2012, 
Momose et al., 2011). Here we have identified the first motor able to do so. Lack of KIF13A was 
found to reduce viral titers (Fig 1A), without affecting initial stages of viral infection (Fig 1C,D) or 
the delivery of virion-forming viral proteins (HA and M2) (Fig 2F) to sites of viral assembly, but 
impacting on vRNP localization. In the context of overexpression, KIF13A biased the distribution 
of vRNPs and Rab11 towards the periphery in three different conditions: normal infection (Fig 3, 
S2, S3, S4), upon nucleozin-treatment (Fig 5, S3, S4) or when Rab11 was artificially tagged to 
the mitochondria (Fig6, S5, S6). Immunoprecipitation experiments of KIF13A-WT, selectively 
retrieved Rab11a and Rab11b, but at low levels, which might justify the failure to show vRNP 
associated to the complex (Fig 4). This association between Rab11 and KIF13A was further 
corroborated by the nucleozin and mitoRab11a/b strategies that placed all the components in 
close proximity at the plasma membrane (Fig 5, 6, S2-6). Together these results support the 
model of Fig 7, in which, conversely to what was observed for FIPs (and presumably the 
molecular motors these attract), KIF13A binding to Rab11 vesicles is not disrupted by infection 
and facilitates vRNP transport to the periphery.  
The accumulating data regarding alterations in the Rab11 pathway has led to the proposal 
that, in IAV infection, Rab11 might not be the final factor delivering vRNPs to the surface, 
handing vRNPs to an additional host protein(s) prior to reaching the membrane (Eisfeld et al., 
2015, Vale-Costa et al., 2016, Vale-Costa and Amorim, 2016a). In agreement, a very recent 
paper provides evidence of a step in the cytoplasmic transport of influenza vRNPs that is 
independent of Rab11a (Nturibi et al., 2017). Our results show KIF13A-WT accumulating at the 
plasma membrane (Figs 3, 5, 6, S2-S6) juxtaposed to vRNPs and Rab11, supporting that 
KIF13A operates in a Rab11 dependent manner. However, the way-station hypothesis might not 
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be discarded, as vRNPs might be transferred from Rab11 to other cell factor(s) and slide to the 
cell surface by the action of molecular motors distinct from KIF13A.  
It has been shown that impairment of Rab11 vesicular flow leads to clustering of vesicles 
(Vale-Costa et al., 2016), but the step(s) affected have not been fully understood. Here we 
focused on vesicular transport on microtubules without investigating other steps required for 
vesicular flow (biogenesis, attachment and fusion) that also lack characterization. It is clear that 
in IAV infection, KIF13A does not prevent vesicular clustering late in infection, although it 
contributes to deliver vRNP-laden Rab11 vesicles to the surface. Whether KIF13A contributes to 
vesicular clustering requires further investigation. One attractive hypothesis is that at late stages 
of infection the virus reduces the levels of KIF13A (Fig1B), thus aggravating the impairment in 
vesicular transport. Other mechanisms might contribute to halt the Rab11 pathway during IAV 
infection. Alterations in the cytoskeletal structure have been reported to create obstacles to 
vesicular transport, leading to pausing and movement inhibition (Gramlich et al., 2017, Verdeny-
Vilanova et al., 2017). IAV has been shown to alter the structure of microtubules, and of their 
associated proteins and enzymes, resulting for example in enhanced microtubule acetylation, a 
modification shown to affect microtubule-based movement (Badding and Dean, 2013). However, 
these alterations in vRNP transport have not been analysed (Husain and Harrod, 2011). Another 
parameter worth investigating is how the loading of heavy and large vRNPs influences vesicular 
transport (Verdeny-Vilanova et al., 2017). Seminal studies imaged fully assembled IAV genomes 
budding at the plasma membrane (Fournier et al., 2012, Sugita et al., 2013). However, the 
precise cellular location where genome assembly takes place remains unclear. Recent 
manuscripts suggested that genome assembly involves formation of vRNP sub-bundles (Chou 
et al., 2013, Lakdawala et al., 2014). Formation of sub-bundles could lead, or at least contribute, 
to a halt in vesicular movement resulting in clustering of Rab11 vesicles. Whether clustering of 
Rab11 vesicles triggers genome assembly or results from partial genome assembly (creating an 
environment that could facilitate its completion) is still unclear (Vale-Costa et al., 2016, Vale-
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Costa and Amorim, 2016a). Intriguingly, studies employing high resolution electron microscopy 
found no clear evidence of supramolecular complexes in the areas of clustered vesicles (Vale-
Costa et al., 2016), although it is very likely that the resolution required for such claim has not 
been attained. All these studies highlight the fact that the assembly of IAV genome is far from 
understood. Fascinating outstanding questions that await clarification include: do vRNPs reach 
the budding sites at the plasma membrane as a sort of supramolecular complex (sub-bundle or 
complete genome)?; Does vesicular clustering contribute to viral assembly?; What are the 
molecular mechanisms leading to vesicular clustering?; Is Rab11 the final carrier of vRNP-
containing vesicles to the plasma membrane?; and finally, what other means does the virus 
explore to transport vRNPs (and other viral proteins) to assembly sites?  
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MATERIALS AND METHODS: 
Cells, viruses, plaque assays, infections and drugs: 
Human epithelial embryonic kidney (HEK293T) (gift from Dr Colin Adrain, IGC, Portugal), 
cervical HeLa and alveolar basal cells (A549), and Madin-Darby canine kidney cells (MDCK) 
were cultured as before (Amorim et al., 2011). Cell lines were a kind gift of Prof Paul Digard, 
Roslin Institute, UK. All cells are regularly tested for mycoplasma contamination. Reverse-
genetics derived A/Puerto Rico/8/34 (PR8; H1N1) was used as a model virus (de Wit et al., 
2004) and titrated according to reference (Matrosovich et al., 2006). Statistical analysis of data 
was done using non-parametric Kolmogorov-Smirnov tests. Additional statistical analyses 
included a two-way ANOVA test (to include time), followed by Turkey’s or Sidak’s multiple 
comparison test (*p<0.05, **p<0.01, ***p<0.001, ns non-significant). Virus infections were 
performed at a multiplicity of infection (MOI) of 3 (normally as in (Amorim et al., 2011) to 10 (for 
the mitoRab11 experiment as in (Vale-Costa et al., 2016)). After 30 min, cells were overlaid with 
DMEM containing 0.14% bovine-serum-albumin. The drug nucleozin (Kao et al., 2010) (Prof. 
Richard Kao, University of Hong Kong, China) dissolved in DMSO, was used at a final 
concentration of 2 M. Reverse genetic plasmids were contributed by Dr Ron Fouchier, 
Erasmus MC, Netherlands.  
 
Plasmids produced during this study: 
Plasmids encoding GFP-tagged KIF13A-WT and GFP-KIF13A-ST were sub-cloned into pEGFP-
C2 using SacI and SalI restriction sites subsequently from being amplified using plasmids 
described in (Delevoye et al., 2014). KIF13A-WT and ST were amplified from pKIF13A-YFP 
(Graça Raposo). Plasmid encoding cherry-Rab11bWT was produced by PCR-amplification of 
cDNA from HeLa cells and cloning into EcoRI–BamHI in pcherry-C2 (Clontech). MitoCherry-
Rab11b constitutively active (CA) plasmid was produced from cherry-Rab11b. Constitutively 
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active mutation (Q70L) was introduced by site-directed mutagenesis and fused to the first 105 
base pairs of the Tom20 MTS cloned upstream of Cherry–Rab11bCA using NheI–AgeI sites.  
The following primers were used:  
KIF13A-WT Rv: tcgaGAGCTCAATGTCGGATACCAAGGTAAAAG;  
KIF13A-ST Rv: tcgaGAGCTCAAGGATTGTGAACCATGCTG;  
KIF13A-WT and ST Fw: tcgaGTCGACTCATTGACAGCACAGAAC;  
Rab11b Rv: TGCGGATCCTCACAGGTTCTGGCAGCA;  
Rab11b Fw: ATGCGAATTCATGGGGACCCGGGAC; 
mitoRab11b Rv: ATGCGGATCCTCACAGGTTCTGGCAGCA;  
mitoRab11b Fw: ATGCGAATTCATGGGGACCCGGGAC;  
CA mutation Rv:  GGTAGCGCTCCAGGCCAGCGGTG;  
CA mutation Fw: CACCGCTGGCCTGGAGCGCTACC; 
Tom 20 Rv: ATGCACCGGTTTGAAGTTGGGGTCACTTCG;  
Tom 20 Fw: ATGCGCTAGCATGGTGGGTCGGAACAGC. 
 
Transfections of plasmids and siRNA:  
Cells (HEK293T or HeLas), 70% confluent in 10-cm dishes were transfected with 250 ng of 
indicated plasmids using Lipofectamine 2000 (Life Technologies) and Opti-MEM (Life 
Technologies), according to manufacturer’s instructions. 24h post-transfection cells were 
infected or mock infected at indicated MOI. siRNA transfection of the KIF13A 
(CTGGCGGGTAGCGAAAGAGTA, S103019800) and negative control (NT, 1022076) RNA 
duplexes (QIAGEN) was performed in HEK293T and A549 cells grown to approximately 50% 
confluency the day before transfection. Cells were transfected in 6-well plates (100pmol/well) 
using DharmaFECT (Dharmacon). When needed 36h later, cells were transfected as above. 
The mitoRab11a/b experiments was done as in (Vale-Costa et al., 2016), except that plasmids 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
transfected along with mitoRab11 or mitocherry included GFP, or GFP-KIF13A-WT or GFP-
KIF13A-ST. 
Real-time reverse-transcription PCR 
Extraction of RNA from samples in NZYol (NZYtech, MB18501) was made using the Direct-zol 
RNA minipreps (Zymo Research, R2052). Reverse transcription was performed using the 
transcriptor first strand cDNA kit (Roche, 04896866001). Real-time RT-PCR to detect GAPDH 
and KIF13A was prepared in 384-well, white, thin wall plates (Biorad, HSP3805) using SYBR 
Green Supermix (Biorad, 172-5124), 10%(v/v) of cDNA and 0.4M of each primer (KIF13A Fw: 
GAAGGGAATCAAACGGTCCT; KIF13A Rv: AAACCACTTCTTGACCAGCG; GAPDH Fw: 
CTCTGCTCCTCCTGTTCGAC; GAPDH Rv: ACCAAATCCGTTGACTCCGAC). 
The reaction was performed on a CFX 384 Touch Real-Time PCR Detection System machine 
(Biorad), using the following PCR conditions: Cycle 1 (1 repeat): 95ºC for 2 minutes; Cycle 2 (40 
repeats): 95ºC for 5 seconds and 60ºC for 30 seconds; Cycle 3: 95°C for 5 seconds and melt 
curve 65ºC to 95ºC (increment 0.05ºC each 5 seconds). Data was analysed using the CFX 
manager software (Biorad). 
Confocal Microscopy  
Immunofluorescence assays were performed as in (Simpson-Holley et al., 2002). Antibodies 
used: rabbit polyclonal against Rab11a (1:100; Life Technologies, 715300); mouse monoclonal 
against NP (1:1000; Abcam, 20343). Secondary antibodies were all from the Alexa Fluor range 
(1:1000; Life Technologies).  Single optical sections were imaged with a Leica SP5 live or 
inverted confocal microscope and post-processed using ImageJ (National Institutes of Health; 
NIH) software for analyses: For vesicle-size analysis (area in m2), images were converted to 8-
bit color and a ‘background subtraction’ of 20 pixels applied. Subsequently, ‘threshold’ was 
adjusted to 14 (lower level) – 255 (upper level), followed by ‘analyze particle’ function to quantify 
each vesicle inside selected cells. Frequency distributions were calculated and plotted using 
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intervals of [0-0.15], [0.15-0.30] and above 0.30 m2; to calculate Pearson correlation 
coefficient, the ‘Coloc 2’ function was used; to quantify the percentage of NP and Rab11 
perinuclear staining, perinuclear region was defined using the nucleus, delineated by DAPI 
staining that was then enlarged by 2 μm towards the plasma membrane. This 2 μm region was 
used to measure intensity of NP (and of Rab11) using integrated density that was divided by the 
integrated density of NP (and Rab11) staining of the entire cytoplasm. Cell membrane was 
defined using WGA staining; To quantify accumulation at the periphery the cell edge was 
defined with WGA, decreased by 2 or 3 m. The intensity of NP (and of Rab11) was measured 
within this region using integrated density and divided by the integrated density of NP (and 
Rab11) staining of the entire cytoplasm.  All graphs were plotted using GraphPad Prism. 
Statistical analysis of data was performed using two-way ANOVA test, followed by Turkey’s or 
Sidak’s multiple comparison test (*p<0.05, **p<0.01, ***p<0.001, ns non-significant).  At least 25 
cells were analysed per condition.  
 
Flow Cytometry: 
A549 cells were prepared for flow cytometry analysis by detaching from the wells with trypsin, 
followed by fixation with 4% paraformaldehyde and washing with PBS in between steps. Cell 
suspensions were then resuspended in FACS buffer (PBS / 4% FBS). Antibodies used for 
immunofluorescence staining were: rabbit polyclonal against HA (anti-PR8, 1:500, kind gift from 
Prof Paul Digard) and M2 (1:100, Abcam, 56086). Secondary antibodies were from Alexa range 
(1:1000; Life Technologies). Analysis of cell populations was performed in a Becton Dickinson 
(BD, Franklin Lakes, NJ, USA) FACSCalibur equipped with BD CELLQuest and FlowJo (Tree 
Star Inc., Ashland, OR, USA) softwares. 
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 Pull-down and Western blotting  
Pull down of GFP bound KIF13A was performed using the GFP magnetic agarose beads 
(ChromoTek, gtm-20). HEK293T cells transfected either with GFP or GFP-KIF13A-WT or GFP-
KIF13A-ST and with Cherry-Rab11a WT or Cherry-Rab11b WT were infected or mock infected 
at an MOI of 5 24h post-transfection. At indicated times, cells were lysed in 500 μl of the 
provided lysis buffer containing 1 mM phenylmethylsulfonyl fluoride and protease inhibitor 
cocktail (Roche) on ice for 30 min. Clarified samples were incubated overnight at 4°C with 20 μl 
GFP-Trap_M beads. Pelleted beads were washed extensively with lysis buffer and bound 
proteins were eluted by boiling in SDS-PAGE buffer containing 2.5% β-mercaptoethanol.  
Western blotting was performed according to standard procedures and imaged using a LI-COR 
Biosciences Odyssey near-infrared platform, as described previously (Bruce et al., 2009). 
Antibodies used included mouse monoclonal against Rab11 (1:500; Abcam, 78337) and NA 
(7D8, 1:100, gift from Susanna Colaco, University of Cambridge); rabbit monoclonal against 
virus nucleoprotein (1:2000), and polyclonal against PB1, NS1 and HA (all at 1:500) and 
provided by Prof Paul Digard; goat polyclonal against GFP (1:2000; Sicgen, AB0020) and M1 
(1:500, Abcam, 20910); The secondary antibodies used were from IRDye range (1:10,000; LI-
COR Biosciences).  
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Figures 
 
 
 
 
Fig 1. KIF13A depletion leads to a drop in virus titres, without affecting viral protein 
expression.  
A549 cells were treated with non-targeting or KIF13A specific siRNAs and infected or mock-
infected with PR8 at a multiplicity of infection (MOI) of 3. At the indicated time points A. 
supernatants were collected and viral production evaluated by plaque assays, or cells were 
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collected. Statistical analysis of data was performed using non-parametric Kolmogorov-Smirnov 
test, unpaired (*p<0.05) and B. KIF13A expression was evaluated at the level of transcription by 
RT-qPCR in relation to GAPDH; and C. of viral protein expression of PB1, HA, NA, NP, NS1, M1 
and the control GAPDH by western blotting. Expression of viral proteins was quantified and 
normalized to GAPDH and presented as percentage of each protein in the non-targeting siRNA 
condition at 10h D. Data is shown as means±SEM from four independent experiments and 
statistical significance is indicated as **p <0.01, ***p <0.001 by non-parametric two-way ANOVA 
tests followed by Tukey multiple comparison test.  
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 Fig 2. KIF13A depletion reduces the levels of vRNPs close to the plasma membrane, but 
not that of the viral transmembrane HA and M2 proteins.  
A549 cells were treated with non-targeting or KIF13A specific siRNAs and infected or mock-
infected with PR8 at a MOI of 3. At indicated time points, cells were fixed and processed for 
immunofluorescence staining of endogenous Rab11 (red) and viral NP protein (as proxy for 
vRNPs and in green) A. Images were acquired at a SP5 confocal microscope (scale 
bar=10m). The panels on the right show NP staining (black & white) within 2 μm from the cell 
edge that was obtained as demonstrated in E.; and B. 50 cells per condition were evaluated and 
quantified for nuclear, nuclear-cytoplasmic or cytoplasmic localisation of NP. Statistical analysis 
was performed using two-way ANOVA followed by Sidak’s multiple comparison test. C. Pearson 
correlation for NP and Rab11 was calculated at least on 50 cells per condition in three 
independent replicates using the Fiji plugin co-localization threshold. Statistical analysis was 
performed using one-way ANOVA followed by Kruskal-Wallis multiple comparison test and were 
considered significant at *p<0.05. D. The frequency distribution of three size categories in the 
areas (in m2) of Rab11-vesicles (small, medium and large) was calculated based on NP 
staining and plotted. Statistical analysis of data was performed using an ANOVA test and were 
considered significant at *p<0.05. 30 cells were analyzed per condition in four independent 
experiments. Statistical analysis herein indicated compares only the larger interval of all 
samples for the four replicates. E. The percentage of NP at the edge of the cell was quantified 
by calculating the ratio in NP intensity within 2 μm from the plasma membrane in relation to NP 
intensity of the whole cell. The value of 30 cells in three replicates was plotted and analysed 
statistically using one-way ANOVA followed by Tukey’s multiple comparisons test and were 
considered significant at ***p<0.001. F. A549 cells were treated with non-targeting or KIF13A 
specific siRNAs and infected or mock-infected with PR8 at a MOI of 3. At 10h p.i., the surface 
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levels of viral HA and M2 proteins were analysed by flow cytometry and plotted as percentage in 
arbitrary units. Statistical analysis was done using one-way ANOVA followed by Sidak method to 
compare samples for three replicates and were considered significant at *p<0.05. 
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Fig 3. KIF13A overexpression biases NP distribution to the cell edge and requires KIF13A 
binding to microtubules.  
 HeLa cells were transfected with A. GFP B. GFP-KIF13A-WT or C. GFP-KIF13A-ST. These 
KIF13A forms are depicted in D. A-C, 24h post-transfection cells were infected (or mock-
infected) with PR8 at a MOI=3 and fixed at 8h p.i. and stained for NP (red), endogenous Rab11 
(grey) and counterstained with DAPI (scale bar=10m). E. The percentage of NP at the edge of 
the cell was quantified by calculating the ratio in NP intensity within 2 μm from the plasma 
membrane in relation to NP intensity of the whole cell. The value of 25 cells from three 
replicates was plotted and analysed statistically using one-way ANOVA followed by Tukey’s 
multiple comparisons, and were considered significant at **p<0.01 and ***p<0.001. 
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Fig 4. KIF13A-WT and -ST pull down Rab11a and Rab11b.  
293T cells were transfected individually with GFP, or GFP-KIF13A-WT or GFP-KIF13A-ST in 
combination with either cherry-Rab11a-WT or Cherry-Rab11b-WT. 24h post-transfection cells 
were infected (or mock-infected) with PR8 at a MOI=3 and at 8h p.i., GFP was 
immunoprecipitated using GFP-TRAP. Input (1% of total) and pulled down complexes (80% of 
total) were separated by electrophoresis and KIF13A, NP and Rab11 analysed by western blot. 
The western blot is representative of three independent experiments.  
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Fig 5. Nucleozin-induced collapse of vRNP aggregates close to the nucleus is less 
pronounced in the presence of KIF13A.  
HeLa cells were transfected individually with GFP, or GFP-KIF13A-WT or GFP-KIF13A-ST. 24 h 
post-transfection cells were infected (or mock-infected) with PR8 at a MOI=3 and at 8h p.i. 2 μM 
nucleozin was added and incubated for 2h. Cells were then fixed and stained for NP (red) and 
Rab11 (grey) and counterstained with DAPI A. Representative images of three independent 
experiments (scale bar=10m). B. The percentage of vRNPs (by measuring NP) and Rab11 
close to the nucleus (within 2 μm) relative to that found in the whole cell was quantified in 60 
cells and plotted. The value of 20 cells in three replicates was plotted and analysed statistically 
using two-way ANOVA followed by Tukey’s multiple comparisons test and were considered 
significant at ***p<0.001. C. Model to explain how KIF13-WT counteracts the action of 
nucleozin. It was reported that nucleozin has affinity for two binding sites on NP and hence 
crosslinks colliding vRNP-laden Rab11 vesicles leading to large agglomerates that collapse near 
the nucleus. In our experimental set up, addition of GFP did not affect the collapse of 
vRNPs/Rab11, but that of KIF13A-WT resulted in decreased perinuclear levels of vRNPs, 
suggesting that KIF13A counteracts nucleozin action by pulling vRNPs away from the minus 
end. KIF13A action required binding to microtubules, as the mutant KIF13A-ST was unable to 
counteract nucleozin action. D. Pearson correlation value between GFP-x (x=-,KIF13A-WT, 
KIF13A-ST) and NP or Rab11, as well as between NP and Rab11 in the presence and absence 
of nucleozin was calculated at least on 50 cells per condition in three independent replicates 
using the Fiji plugin co-localization threshold. Statistical analysis was performed using one-way 
ANOVA followed by Kruskal-Wallis multiple comparison test. Letters (a, b and c) are coding for 
comparisons that are significant at least at **p<0.01. 
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Fig 6. KIF13A-WT biases the localisation of mitochondria to the periphery when artificially 
expressing Rab11a or Rab11b.  
HeLa cells were transfected individually with GFP, or GFP-KIF13A-WT or GFP-KIF13A-ST and 
mitocherry or mitoRab11a or mitoRab11b. 24h post-transfection cells were infected (or mock-
infected) with PR8 at a MOI=10. At 14h p.i, cells were fixed and stained for NP (grey) and 
Rab11 (red) and counterstained with DAPI A. Representative images of three independent 
experiments (scale bar=10m). B. Diagram explaining the strategy used to artificially target 
cherry, Rab11a or Rab11b to the mitochondria. C. Pearson correlation value between NP and 
mitocherry/mitoRab11 were calculated for 20 cells per condition from independent replicates 
using the Fiji plugin co-localization threshold. Statistical analysis was performed using one-way 
ANOVA followed by Kruskal-Wallis multiple comparison test. D. The percentage of 
NP/mitoRab11a/b at the edge of the cell was quantified by calculating the ratio in NP intensity 
within 3 μm from the plasma membrane in relation to NP/mitoRab11a/b intensity of the whole 
cell. The value of at least 20 cells in three replicates was plotted and analysed statistically using 
one-way ANOVA followed by Sidak’s multiple comparisons test and were considered significant 
at *p<0.05, **p<0.01 and ***p<0.001.  
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Fig 7. Model for molecular motor recruitment of Rab11-vesicles during IAV infection.  
In the healthy cell, GTP bound Rab11 associates with FIPs that are able to recruit members of 
the three types of molecular motors known: kinesins, dynein and myosin. In addition GTP-
Rab11 is also able to attract molecular motors independently of FIPs as is the case of KIF13A. 
We previously showed that in IAV infected cells, vRNPs outcompete FIPs for Rab11 binding 
(Vale-Costa et al., 2016). In the present study we report that the molecular motor KIF13A is able 
to bind and transport vRNP-Rab11 carrying vesicles. At late stages of infection the levels of 
KIF13A are reduced and might affect transport (hence the dashed line indicating movement). 
The molecular players mediating the interaction in our system are still unclear. 
 
 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
Supplementary Figures 
Figure S1 - KIF13A protein levels are efficiently reduced by siRNA treatment.  
A. A549 cells were treated with non-targeting or KIF13A specific siRNAs and infected or mock-
infected with PR8 at a multiplicity of infection (MOI) of 3. At indicated time points, cells were 
collected and KIF13A and GAPDH levels analysed by western blot. B. HeLa cells were treated 
with non-targeting or KIF13A specific siRNAs and transfected with GFP or GFP-KIF13A-WT or 
a GFP-KIF13A-WT mutant that is resistant to the siRNA duplexes used and incubated for 24h. 
The GFP-KIF13A siRNA resistant (siR) mutant was generated based on the GFP-KIF13A WT 
plasmid, by insertion of two mutations using site-directed mutagenesis (Agilent). The following 
primers were used: 5′- GTAAGGTCAGCTTGGTAGACCTAGCAGGGAGCGAAAGAGTATCTA -
3′ (KIF13A siR Fw); 5′- TAGATACTCTTTCGCTCCCTGCTAGGTCTACCAAGCTGACCTTAC -3’ 
(KIF13A siR Rv). KIF13A was analysed by western blotting and compared to α-tubulin loading 
control. Images are representative of at least three independent experiments. 
J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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Figure S2. KIF13A overexpression biases NP distribution to the cell edge and requires 
KIF13A binding to microtubules.   
HeLa cells were transfected with A. GFP B. GFP-KIF13A-WT or C. GFP-KIF13A-ST. A-D, 24 h 
post-transfection cells were infected (or mock-infected) with PR8 at a MOI=3 and fixed at the 
indicated time points and stained for NP (red) and counterstained with DAPI. D. Shows several 
inlets of infected cells at 8h p.i.. Scale bar represents 10 μm. Images are representative of six 
independent experiments. 
J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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Figure S3 - Nucleozin treatment is not efficient in mock infected cells.  HeLa cells 
were transfected individually with 250 ng of GFP, or GFP-KIF13A WT or GFP-KIF13A ST and 
incubated for 24 hours before being overlaid with Opti-MEM for 8 h prior to being overlaid with 
SFM containing (+) or not (-) 2 μM nucleozin for 2 h. Cells were then fixed and stained for NP 
(Red) and Rab11 (grey). Note that when GFP-KIF13A WT is present, endogenous Rab11 
concentrates at the cell periphery, co-localising with KIF13A. Scale bar represents 10 μm. 
Images are representative of three independent experiments. 
J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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Figure S4 - KIF13A reduces nucleozin-induced perinuclear localization of vRNPs and 
Rab11 in infected cells.  HeLa cells were transfected individually with 250 ng of GFP, or GFP-
KIF13A WT or GFP-KIF13A ST and incubated for 24 hours before being infected with PR8 at a 
MOI of 20.  8 h p.i. cells were treated (+) or not (-) with 2 μM nucleozin for 2 h. Cells were then 
fixed and stained for NP (Red) and Rab11 (grey). Note that nucleozin treatment induces 
formation of vRNP (and Rab11) aggregates as described in (Amorim et al., 2013). In the 
presence of GFP-KIF13A-WT, aggregates do not concentrate so close to the nucleus, as in the 
presence of GFP or GFP-KIF13A-ST, a form unable to attach to molecular motors. Scale bar 
represents 10 μm. Images are representative of three independent experiments. 
J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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Figure S5 - KIF13A-WT biases mitoRab11a and vRNP to the periphery.  
A. HeLa cells were transfected with GFP-FIP5 and mitocherry or mitoRab11aCA and incubated 
for 14h, before being fixed and processed for imaging. DAPI was included to stain the nucleus. 
Pearson correlation values between GFP-FIP5 and mito were calculated for 10 cells using the 
Fiji plugin co-localization threshold. This analysis was meant to corroborate published material 
(Vale-Costa and Amorim, 2016a). Statistical analysis was performed using one-way ANOVA 
followed by Kruskal-Wallis multiple comparison test (**p<0.01). B,C. HeLa cells were 
transfected with GFP, GFP-KIF13A-WT or GFP-KIF13A-ST and with mitocherry or 
mitoRab11aCA and infected (or mock infected) with PR8 at MOI 10. At 14h p.i., cells were fixed 
and processed for immunofluorescence staining of viral NP (Scale bar = 10 μm). Note that 
vRNPs relocate to mitochondria exclusively in the presence of mitoRab11a. Images are 
representative of three independent experiments. 
J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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Figure S6 - KIF13A-WT biases mitoRab11a to the periphery in uninfected cells and 
requires its motor activity. HeLa cells were transfected individually with GFP, or GFP-KIF13A-
WT or GFP-KIF13A-ST and mitocherry or mitoRab11a or mitoRab11b for 32h, time at which 
cells were fixed and stained for NP (red), Rab11 (grey) and counterstained with DAPI (blue) 
(scale bar=10m). Images are representative of three independent experiments. 
J. Cell Sci. 130: doi:10.1242/jcs.210807: Supplementary information
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